Advanced BiomedADVB +3.10%12 EBIT per Share is $-3.03 as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 168 Medical Diagnostics & Research companies, Advanced Biomed ranks worse than 99.4% on this metric.
Advanced Biomed's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.38.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.03.
During the past 3 years, the average EBIT per Share Growth Rate was -97.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Advanced Biomed's EBIT per Share or its related term are showing as below:
ADVB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -97.9 Med: -54.65 Max: -11.4
Current: -97.9
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Advanced Biomed was -11.40% per year. The lowest was -97.90% per year. And the median was -54.65% per year.
ADVB's 3-Year EBIT Growth Rate is ranked worse than 99.4% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75
vs ADVB: -97.90
Advanced Biomed's EBIT for the
three
months ended in Mar. 2026 was $-0.49 Mil.
Advanced Biomed (NAS:ADVB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Advanced Biomed EBIT per Share Related Terms
Advanced Biomed EBIT per Share Historical Data
* Premium members only.
The historical data trend for Advanced Biomed's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Biomed (ADVB) has a EBIT per Share of $-3.03 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #167 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 99.4%.
Is Advanced Biomed's EBIT per Share too high?
Advanced Biomed's current EBIT per Share is $-3.03. Based on the distribution chart, Advanced Biomed ranks #167 out of 168 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's EBIT per Share compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #167 out of 168 companies for EBIT per Share. This places Advanced Biomed in the lower half of its industry. The industry median EBIT per Share is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Advanced Biomed and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Biomed's current EBIT per Share is $-3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current EBIT per Share of $-3.03. The current EBIT per Share is $-3.03. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current EBIT per Share is $-3.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score
Get the complete analysis for ADVB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADVB has been successfully added to your 
